GlassScriptPhysician profile
Craig M Stein
NPI 1861487456
$9,252.47
in general payments reported to CMS, 2019-2025
37 companies · $1,400 in 2025
The $1,400 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $1,049 · 2021: $1,653 · 2022: $1,318 · 2023: $1,579 · 2024: $1,387 · 2025: $1,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,365.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,567.47 | 2019-2025 | Rinvoq, Linzess, Mavyret |
| Gilead Sciences, INC. | $1,044.07 | 2019-2025 | |
| Pfizer INC. | $894.17 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $648.53 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $375.86 | 2019-2024 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $275.44 | 2019-2025 | Tremfya |
| Celgene Corporation | $273.48 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $253.89 | 2019-2024 | Rebyota |
| Ardelyx, INC. | $245.17 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $234.23 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $196.67 | 2019-2024 | Linzess |
| Glaxosmithkline, LLC. | $145.78 | 2019-2021 | |
| Genzyme Corporation | $141.40 | 2025 | |
| Lilly USA, LLC | $112.19 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $87.64 | 2023-2025 | Dupixent |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $74.50 | 2020-2021 | |
| Qol Medical, LLC | $63.41 | 2019-2024 | Sucraid |
| Intercept Pharmaceuticals, INC. | $61.49 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $60.93 | 2024-2025 | Iqirvo |
| Shionogi INC | $55.20 | 2019-2020 | |
| Capsovision, INC. | $49.04 | 2023-2024 | Capsocam Plus |
| Medtronic, INC. | $46.41 | 2022-2024 | Interstim, Gi Genius |
| Phathom Pharmaceuticals, INC. | $42.44 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $41.62 | 2019-2021 | |
| Amgen INC. | $36.55 | 2021-2022 | |
| Organon LLC | $33.14 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.58 | 2023-2024 | Cyltezo |
| Braintree Laboratories, INC. | $25.35 | 2019-2021 | |
| Biocon Biologics INC | $21.96 | 2025 | Yesintek |
| Endo Pharmaceuticals INC. | $20.22 | 2020 | |
| Evoke Pharma, INC. | $17.96 | 2024 | |
| Pentax of America, INC. | $16.45 | 2022 | |
| Ucb, INC. | $15.83 | 2019 | |
| Axonics, INC. | $14.89 | 2021 | |
| Madrigal Pharmaceuticals | $14.12 | 2025 | Rezdiffra |
| Shire North American Group INC | $12.39 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$51,948.79 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.